Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Ismat Lotia FarrukhNathalie LachenalMalik M AdenovSaman AhmedYerkebulan AlgozhinSylvine CoutissonEpifanio Sánchez GaravitoCatherine HewisonDavid HoltzmanHelena HuergaAleeza JanmohamedPalwasha Y KhanGamarly Leblanc JacquesNino LomtadzeNara MelikyanCarole D MitnickGulnaz MussabekovaElna OssoSara PereaFauziah Asnely PutriMahmud RashidovMichael L RichYekaterina SakhabutdinovaKwonjune J SeungAssel StambekovaDante Vargas VásquezMolly F FrankeUzma KhanPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.
Keyphrases
- multidrug resistant
- mycobacterium tuberculosis
- drug resistant
- gram negative
- acinetobacter baumannii
- gestational age
- pregnancy outcomes
- klebsiella pneumoniae
- preterm birth
- pulmonary tuberculosis
- low birth weight
- birth weight
- escherichia coli
- preterm infants
- hiv aids
- metabolic syndrome
- adipose tissue
- skeletal muscle
- pregnant women
- cystic fibrosis
- hiv infected
- hepatitis c virus
- adverse drug
- combination therapy
- replacement therapy
- drug induced
- antiretroviral therapy